echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Roche PD-L1 monoanti-Tecentriq joint targeted therapy: FDA approved for treatment of advanced melanoma.

    Roche PD-L1 monoanti-Tecentriq joint targeted therapy: FDA approved for treatment of advanced melanoma.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Roche announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 monoantitic Tecentriq joint MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelmurabraf for the treatment of patients with braF V600 mutation-positive advanced melanoma.
    the BRAF protein mutates in almost all melanoma patients.
    Photo Source: The approval is based on the results of a three-phase study of Imspire150, a combination of treatments that improved patients' median progression-free survival (PFS) to 15.1 months, compared with 10.6 months for the placebo group. Levi Garraway, chief medical officer of
    Roche Genentech, said: "With the combination of cancer immunotherapy and targeted therapy, braF V600 mutant-positive patients with advanced melanoma can survive for more than 15 months without worsening the disease.
    FDA approval of the Tecentriq portfolio is an important step in the treatment of advanced melanoma.
    " however, Roche could face stiff competition from rival Merck's Keytruda and Baxter's Opdivo, which have been on the market for years as drugs to treat melanoma.
    Keytruda was approved for the treatment of advanced melanoma as early as September 2014, when it became the first drug in the U.S. to be approved for PD-1/L1.
    Opdivo was also approved in 2015 to treat patients with advanced melanoma.
    in addition to melanoma, Roche's Tecentriq is also in the lung cancer, urogenital tract, skin, breast cancer, gastrointestinal, gynaecological and head and neck cancer is undergoing or planned several phase 3 studies.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.